<div id="readability-page-1"><p>Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have received a consensus rating of &#34;Moderate Buy&#34; from the eight analysts that are presently  covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have assigned  a buy recommendation to  the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $100.20.</p><div><p><span></span><span>Get <strong>LeMaitre Vascular</strong> alerts:</span></p></div><p>LMAT has been the subject of a number of recent analyst reports. Cantor Fitzgerald  restated a &#34;neutral&#34; rating and set a $95.00 price target on shares of LeMaitre Vascular in a report on Monday, November 10th. Weiss Ratings  reissued a &#34;buy (b-)&#34; rating on shares of LeMaitre Vascular in a research note on Monday, December 29th. Wells Fargo &amp; Company reduced their target price on LeMaitre Vascular from $97.00 to $93.00 and set an &#34;equal weight&#34; rating on the stock in a research report on Friday, November 7th. Wall Street Zen cut LeMaitre Vascular from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, December 6th. Finally, Roth Mkm  restated a &#34;buy&#34; rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, November 5th.</p><p><b>Get Our Latest Stock Analysis on LeMaitre Vascular</b></p><h2>LeMaitre Vascular Trading Up 0.5%</h2><p>LMAT opened at $87.42 on Friday. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of 37.68, a price-to-earnings-growth ratio of 1.93 and a beta of 0.72. The company's 50 day simple moving average is $84.53 and its two-hundred day simple moving average is $87.66. LeMaitre Vascular has a 1-year low of $71.42 and a 1-year high of $105.55. The company has a debt-to-equity ratio of 0.44, a current ratio of 13.58 and a quick ratio of 11.45. </p><p>LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, beating the consensus estimate of $0.57 by $0.05. The firm had revenue of $61.05 million during the quarter, compared to analysts' expectations of $62.18 million. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.The business's revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.49 earnings per share.  Analysts expect that  LeMaitre Vascular will post 1.94 EPS for the current fiscal year. </p><h2>Hedge Funds Weigh In On LeMaitre Vascular</h2><p>Hedge funds have recently made changes to their positions in the stock. Parkside Financial Bank &amp; Trust increased its holdings in  LeMaitre Vascular by 1,913.3% in the 2nd quarter. Parkside Financial Bank &amp; Trust now owns 302 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 287 shares during the last quarter.  Cornerstone Planning Group LLC boosted its position in shares of  LeMaitre Vascular by 534.0% during the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier's stock worth $30,000 after buying an additional 283 shares during the period.  MAI Capital Management acquired a new stake in shares of  LeMaitre Vascular in the third quarter valued at $38,000.  First Horizon Corp purchased a new stake in shares of  LeMaitre Vascular in the 3rd quarter valued at $39,000.  Finally, Geneos Wealth Management Inc. lifted its stake in  LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after acquiring an additional 398 shares in the last quarter. Hedge funds and other institutional investors own  84.64% of the company's stock. </p><h2>LeMaitre Vascular Company Profile</h2> (Get Free Report)<p>LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.  </p><p>Founded in 1983 by George D.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than LeMaitre Vascular</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>The day the gold market broke</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>Your Bank Account Is No Longer Safe</li><li>He just nailed another gold prediction …</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TE1BVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TE1BVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in LeMaitre Vascular Right Now?</h2><p>Before you consider LeMaitre Vascular, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.</p><p>While LeMaitre Vascular currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LMAT

<p>LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a consensus rating of "Moderate Buy" from eight analysts. Four analysts recommend holding the stock, while four suggest buying. The average 1-year price target is $100.20. Recent reports include a neutral rating from Cantor Fitzgerald with a $95.00 target, and a buy rating from Roth Mkm with a $108.00 target. The company reported $0.62 EPS, beating estimates, with revenue of $61.05 million, up 11.4% year-over-year. Hedge funds own 84.64% of the stock, indicating strong institutional interest.</p>

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Rating of "Moderate Buy" by Brokerages